Effects of intermittent androgen suppression on androgen‐dependent tumors. Apoptosis and serum prostate‐specific antigen

Background. Since postcastration progression of tumors to an androgen‐independent state appears to be linked to the cessation of androgen‐induced differentiation of tumorigenic stem cells, the authors hypothesized that the replacement of androgens at the end of a period of apoptotic regression might result in the regeneration of differentiated tumor cells with further apoptotic potential.

[1]  J. Oesterling,et al.  Hormonal Therapy of Prostate Cancer: Limitations in the Total Androgen Ablation Concept , 1988 .

[2]  M. Terris,et al.  Determination of prostate volume by transrectal ultrasound. , 1991, The Journal of urology.

[3]  S. Goldenberg,et al.  A critical evaluation of a specific radioimmunoassay for prostatic acid phosphatase , 1982, Cancer.

[4]  J. Miller,et al.  The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. , 1992, The Journal of urology.

[5]  N. Bruchovsky,et al.  Hormonal effects on cell proliferation in rat prostate. , 1975, Vitamins and hormones.

[6]  J. Oesterling,et al.  Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. , 1990, The Journal of urology.

[7]  D. Tindall,et al.  Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. , 1991, Cancer research.

[8]  W. Whitmore,et al.  Considerations for the use of testosterone with systemic chemotherapy in prostatic cancer , 1982, Cancer.

[9]  S. Goldenberg,et al.  Use of cyproterone acetate in prostate cancer. , 1991, The Urologic clinics of North America.

[10]  N. Kyprianou,et al.  Quantal relationship between prostatic dihydrotestosterone and prostatic cell content: Critical threshold concept , 1987, The Prostate.

[11]  A. Coldman,et al.  Loss of androgen dependence is associated with an increase in tumorigenic stem cells and resistance to cell-death genes , 1990, The Journal of Steroid Biochemistry and Molecular Biology.

[12]  S. Goldenberg,et al.  The endocrinology and treatment of prostate tumor progression. , 1987, Progress in clinical and biological research.

[13]  J. Oesterling,et al.  Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. , 1991, The Journal of urology.

[14]  L. Klotz,et al.  Intermittent endocrine therapy for advanced prostate cancer , 1986, Cancer.

[15]  M. Gleave,et al.  Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. , 1992, Cancer research.

[16]  N. Sato,et al.  Paracrine growth stimulation of androgen-responsive Shionogi Carcinoma 115 by its autonomous subline (Chiba Subline 2). , 1990, Cancer research.

[17]  A. Coldman,et al.  Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. , 1990, Cancer research.

[18]  R L Vessella,et al.  Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer. , 1987, The Journal of urology.

[19]  J. Kerr,et al.  SUCCESSIVE WAVES OF APOPTOSIS IN THE RAT PROSTATE AFTER REPEATED WITHDRAWAL OF TESTOSTERONE STIMULATION , 1984, Pathology.

[20]  N. Bruchovsky.  The metabolism of testosterone and dihydrotestosterone in an androgen-dependent tumour. A possible correlation between dihydrotestosterone and tumour growth in vivo. , 1972, The Biochemical journal.

[21]  T. Stamey,et al.  Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. , 1989, The Journal of urology.